- Home
- LEGH vs TBPH Comparison
LEGH vs TBPH Comparison
Compare LEGH & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- TBPH
- Stock Information
- Founded
- LEGH 2005
- TBPH 2013
- Country
- LEGH United States
- TBPH United States
- Employees
- LEGH N/A
- TBPH N/A
- Industry
- LEGH Homebuilding
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- TBPH Health Care
- Exchange
- LEGH Nasdaq
- TBPH Nasdaq
- Market Cap
- LEGH 588.8M
- TBPH 545.0M
- IPO Year
- LEGH 2018
- TBPH N/A
- Fundamental
- Price
- LEGH $26.74
- TBPH $13.15
- Analyst Decision
- LEGH Strong Buy
- TBPH Strong Buy
- Analyst Count
- LEGH 2
- TBPH 3
- Target Price
- LEGH $29.00
- TBPH $21.33
- AVG Volume (30 Days)
- LEGH 60.9K
- TBPH 307.4K
- Earning Date
- LEGH 08-07-2025
- TBPH 08-12-2025
- Dividend Yield
- LEGH N/A
- TBPH N/A
- EPS Growth
- LEGH 2.38
- TBPH N/A
- EPS
- LEGH 2.23
- TBPH 0.26
- Revenue
- LEGH $184,284,000.00
- TBPH $77,205,000.00
- Revenue This Year
- LEGH N/A
- TBPH $51.74
- Revenue Next Year
- LEGH $7.69
- TBPH N/A
- P/E Ratio
- LEGH $12.01
- TBPH $51.40
- Revenue Growth
- LEGH 8.79
- TBPH 24.49
- 52 Week Low
- LEGH $21.58
- TBPH $7.88
- 52 Week High
- LEGH $29.25
- TBPH $13.24
- Technical
- Relative Strength Index (RSI)
- LEGH 76.96
- TBPH 78.44
- Support Level
- LEGH $24.50
- TBPH $11.05
- Resistance Level
- LEGH $27.29
- TBPH $11.40
- Average True Range (ATR)
- LEGH 1.06
- TBPH 0.43
- MACD
- LEGH 0.44
- TBPH 0.20
- Stochastic Oscillator
- LEGH 85.71
- TBPH 95.88
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).